Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Previous evidence directly evaluating the efficacy and safety of abiraterone and enzalutamide treatment for castration-resistant prostate cancer (CRPC) is limited. We aim to include more randomized controlled trials (RCTs) to comprehensively assess the efficacy and safety of abiraterone...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiaonan, Zhao, Xiaohui, Xu, Hang, Han, Xin, Xu, He, Dong, Xin, Peng, Ruilin, Yang, Lu, Wei, Qiang, Ai, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946394/
https://www.ncbi.nlm.nih.gov/pubmed/31689828
http://dx.doi.org/10.1097/MD.0000000000017748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946394/
https://www.ncbi.nlm.nih.gov/pubmed/31689828
http://dx.doi.org/10.1097/MD.0000000000017748

Ejemplares similares